Beta-adrenergic blockade and atrio--ventricular conduction impairment.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrioventricular (AV) conduction is crucial for cardiac function.
• Beta-adrenergic blocking agents are widely used to manage cardiovascular conditions.
• Understanding their effects on AV conduction is essential for safe and effective clinical use.

Purpose of the Study:

• To investigate the impact of six beta-adrenergic blocking agents on atrioventricular conduction in dogs.
• To differentiate the roles of beta-blockade, membrane stabilizing effects (MSE), and intrinsic sympathomimetic activity (ISA) in modifying AV conduction.

Main Methods:

• Utilized premature atrial stimuli (St2) following regular stimuli (St1) for atrial pacing in dogs.
• Determined atrial effective refractory period (AERP), nodoventricular effective refractory period (NERP), global effective refractory period (GERP), and global functional refractory period (GFRP).
• Administered six different beta-adrenergic blocking agents and measured refractory periods before and after drug administration.

Main Results:

• Beta-blockade, particularly with agents lacking ISA (e.g., d,l-propranolol, sotalol), significantly increased AERP, NERP, GERP, and GFRP, indicating impaired AV conduction.
• Agents with ISA (e.g., pindolol, practolol) showed less impairment, suggesting a protective role of ISA.
• Membrane stabilizing effects (MSE) were found to be primarily involved in conduction impairment at the Purkinje-free junction, as evidenced by ventricular effective refractory period (VERP) measurements.

Conclusions:

• Beta-blockade is the primary cause of atrioventricular conduction impairment.
• Intrinsic sympathomimetic activity (ISA) likely provides a metabolic protection against AV conduction impairment induced by beta-blockade.
• Membrane stabilizing effects (MSE) play a significant role in conduction impairment specifically at the Purkinje-free junction.